Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

被引：0
|
作者：
Junji Tsurutani
Yukinori Sakata
Toshiyuki Matsuoka
机构：
[1] Kindai University Faculty of Medicine,Department of Medical Oncology
[2] Showa University,Advanced Cancer Translational Research Institute
[3] Eisai Co.,Clinical Planning and Development Department
[4] Ltd.,undefined
来源：
Breast Cancer | 2019年 / 26卷
关键词：
Eribulin; Chemotherapy-induced peripheral neuropathy; Risk factors; Post-marketing study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：235 / 243
页数：8
相关论文
共 50 条
  • [1] Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
    Tsurutani, Junji
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    BREAST CANCER, 2019, 26 (02) : 235 - 243
  • [2] Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin
    Sakata, Y.
    Iwata, H.
    Ikezawa, H.
    Fudetani, R.
    Tonoda, D.
    Uchida, Y.
    Hasegawa, H.
    Matsuoka, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Mechanistic pharmacodynamic analysis on safety profiles of eribulin in patients with breast cancer using data obtained by post-marketing observational study
    Kawamura, Takahisa
    Fermanelli, Valentina
    Takahashi, Toshiaki
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    Ishii, Mika
    Tanigawara, Yusuke
    CANCER RESEARCH, 2017, 77
  • [4] Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
    Junichiro Watanabe
    Yoshinori Ito
    Shozo Ohsumi
    Mitsuhiro Mizutani
    Hideya Tashiro
    Kenichi Sakurai
    Masato Takahashi
    Tsuyoshi Saito
    Junji Tsurutani
    Hirofumi Mukai
    Tetsuhiro Yoshinami
    Shintaro Takao
    Yasuhisa Yamamoto
    Toshiyuki Matsuoka
    Hirotaka Iwase
    Hiroji Iwata
    Seigo Nakamura
    Toshiaki Saeki
    Investigational New Drugs, 2017, 35 : 791 - 799
  • [5] Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
    Watanabe, Junichiro
    Ito, Yoshinori
    Ohsumi, Shozo
    Mizutani, Mitsuhiro
    Tashiro, Hideya
    Sakurai, Kenichi
    Takahashi, Masato
    Saito, Tsuyoshi
    Tsurutani, Junji
    Mukai, Hirofumi
    Yoshinami, Tetsuhiro
    Takao, Shintaro
    Yamamoto, Yasuhisa
    Matsuoka, Toshiyuki
    Iwase, Hirotaka
    Iwata, Hiroji
    Nakamura, Seigo
    Saeki, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 791 - 799
  • [6] Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes.
    Candelario, Nellowe
    Wongrakpanich, Supakanya
    Morginstin, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [7] Characteristics of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
    Sawada, Namie Okino
    Zandonai, Alexandra Paola
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [8] Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients
    Kim, Hye Young
    Kang, Jeong Hee
    Song, Chi Eun
    Youn, Hyun Jo
    ASIAN ONCOLOGY NURSING, 2013, 13 (04) : 222 - 230
  • [9] THE EXPERIENCE OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN BREAST CANCER PATIENTS
    Marin-Chollom, Amanda M.
    Li, Lan A.
    Suarez-Cortes, Estefania
    Castellano, Marisol
    Accordino, Melissa K.
    Trivedi, Meghna S.
    Hershman, Dawn L.
    Greenlee, Heather
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 : S17 - S17
  • [10] Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated With Paclitaxel
    Reyes-Gibby, Cielito C.
    Morrow, Phuong Khang
    Buzdar, Aman
    Shete, Sanjay
    JOURNAL OF PAIN, 2009, 10 (11): : 1146 - 1150
12345